The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review

Coronavirus disease 2019 (COVID-19) is a recently emerging disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Notably, the safety of immunosuppressive medications is a major concern during an infectious disease pandemic. Rituximab (RTX), as a monoclonal antibody against...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pourya Yarahmadi, Mohammad Alirezaei, Seyed Mohammad Forouzannia, Abdorreza Naser Moghadasi
Formato:	article
Lenguaje:	EN
Publicado:	Shiraz University of Medical Sciences 2021
Materias:	rituximab covid-19 sars-cov-2 immune system diseases Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/280ff03242c646f0ab5d6c85e329a954
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:280ff03242c646f0ab5d6c85e329a954
record_format	dspace
spelling	oai:doaj.org-article:280ff03242c646f0ab5d6c85e329a9542021-11-09T06:23:38ZThe Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review0253-07161735-368810.30476/ijms.2021.88717.1946https://doaj.org/article/280ff03242c646f0ab5d6c85e329a9542021-11-01T00:00:00Zhttps://ijms.sums.ac.ir/article_47742_a81878ba0c568c756e2866b54da8121d.pdfhttps://doaj.org/toc/0253-0716https://doaj.org/toc/1735-3688Coronavirus disease 2019 (COVID-19) is a recently emerging disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Notably, the safety of immunosuppressive medications is a major concern during an infectious disease pandemic. Rituximab (RTX), as a monoclonal antibody against CD20 molecule, is widely used for the treatment of various diseases, mostly autoimmune diseases and some malignancies. Previous studies indicated that RTX, as an immunosuppressive medication, may be associated with the increased risk of infections. Moreover, given the wide use of RTX, a necessity of determining the different aspects of RTX use in the COVID-19 era is strongly felt. We reviewed current studies on the clinical courses of patients with SARS-CoV-2 infection. It appears that the use of RTX does not increase morbidity and mortality in most patients. However, underlying diseases and other concomitant medications may play a role in the disease course, while the concerns of vaccine efficacy in patients receiving RTX still need to be addressed. Therefore, more controlled studies are needed for a better conclusion.Pourya YarahmadiMohammad AlirezaeiSeyed Mohammad ForouzanniaAbdorreza Naser MoghadasiShiraz University of Medical Sciencesarticlerituximabcovid-19sars-cov-2immune system diseasesMedicine (General)R5-920ENIranian Journal of Medical Sciences, Vol 46, Iss 6, Pp 411-419 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rituximab covid-19 sars-cov-2 immune system diseases Medicine (General) R5-920
spellingShingle	rituximab covid-19 sars-cov-2 immune system diseases Medicine (General) R5-920 Pourya Yarahmadi Mohammad Alirezaei Seyed Mohammad Forouzannia Abdorreza Naser Moghadasi The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
description	Coronavirus disease 2019 (COVID-19) is a recently emerging disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Notably, the safety of immunosuppressive medications is a major concern during an infectious disease pandemic. Rituximab (RTX), as a monoclonal antibody against CD20 molecule, is widely used for the treatment of various diseases, mostly autoimmune diseases and some malignancies. Previous studies indicated that RTX, as an immunosuppressive medication, may be associated with the increased risk of infections. Moreover, given the wide use of RTX, a necessity of determining the different aspects of RTX use in the COVID-19 era is strongly felt. We reviewed current studies on the clinical courses of patients with SARS-CoV-2 infection. It appears that the use of RTX does not increase morbidity and mortality in most patients. However, underlying diseases and other concomitant medications may play a role in the disease course, while the concerns of vaccine efficacy in patients receiving RTX still need to be addressed. Therefore, more controlled studies are needed for a better conclusion.
format	article
author	Pourya Yarahmadi Mohammad Alirezaei Seyed Mohammad Forouzannia Abdorreza Naser Moghadasi
author_facet	Pourya Yarahmadi Mohammad Alirezaei Seyed Mohammad Forouzannia Abdorreza Naser Moghadasi
author_sort	Pourya Yarahmadi
title	The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
title_short	The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
title_full	The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
title_fullStr	The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
title_full_unstemmed	The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review
title_sort	outcome of covid-19 in patients with a history of taking rituximab: a narrative review
publisher	Shiraz University of Medical Sciences
publishDate	2021
url	https://doaj.org/article/280ff03242c646f0ab5d6c85e329a954
work_keys_str_mv	AT pouryayarahmadi theoutcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT mohammadalirezaei theoutcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT seyedmohammadforouzannia theoutcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT abdorrezanasermoghadasi theoutcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT pouryayarahmadi outcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT mohammadalirezaei outcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT seyedmohammadforouzannia outcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview AT abdorrezanasermoghadasi outcomeofcovid19inpatientswithahistoryoftakingrituximabanarrativereview
_version_	1718441279897993216

The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review

Ejemplares similares